• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接抑制因子 VIIa 的 TFPI 和 TFPI 构建体。

Direct inhibition of factor VIIa by TFPI and TFPI constructs.

机构信息

Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, Netherlands.

出版信息

J Thromb Haemost. 2013 Apr;11(4):704-14. doi: 10.1111/jth.12152.

DOI:10.1111/jth.12152
PMID:23347185
Abstract

BACKGROUND

Tissue factor pathway inhibitor (TFPI) is a multi-Kunitz domain protease inhibitor that down-regulates the extrinsic coagulation pathway by inhibiting FXa and FVIIa.

OBJECTIVES

To investigate the role of the three Kunitz domains (KDs) of TFPI in FVIIa inhibition using full-length TFPI (TFPIfl ) and truncated TFPI constructs.

METHODS

Inhibition of FVIIa with/without relipidated tissue factor (TF) or soluble TF (sTF) by TFPIfl /TFPI constructs was quantified with a FVIIa-specific chromogenic substrate.

RESULTS AND CONCLUSIONS

TFPIfl inhibited TF-FVIIa via a monophasic reaction, which is rather slow at low TFPIfl concentrations (t½  ≈ 5 min at 2 nm TFPI) and has a Ki of 4.6 nm. In the presence of sTF and without TF, TFPIfl was a poor FVIIa inhibitor, with Ki values of 122 nm and 1118 nm, respectively. This indicates that phospholipids and TF significantly contribute to FVIIa inhibition by TFPIfl . TFPI constructs without the KD3-c-terminus (TFPI1-150 and KD1-KD2) were 7-10-fold less effective than TFPIfl in inhibiting TF-FVIIa and sTF-FVIIa, indicating that the KD3-C-terminus significantly contributes to direct inhibition of FVIIa by TFPI. Compared with KD1-KD2, KD1 was a poor TF-FVIIa inhibitor (Ki =434 nm), which shows that the KD2 domain of TFPI also contributes to FVIIa inhibition. Protein S stimulated TF-FVIIa inhibition by TFPIfl (Ki =0.7 nm). In the presence of FXa, a tight quaternary TF-FVIIa-TFPI-FXa complex is formed with TFPIfl , TFPI1-150 and KD1-KD2, with Ki values of < 0.15 nm, 0.5 nm and 0.8 nm, respectively, indicating the KD3-C-terminus is not a prerequisite for quaternary complex formation. Phospholipids and the Gla-domain of FXa are required for quaternary complex formation.

摘要

背景

组织因子途径抑制剂(TFPI)是一种多 Kunitz 结构域蛋白酶抑制剂,通过抑制 FXa 和 FVIIa 来下调外源性凝血途径。

目的

使用全长 TFPI(TFPIfl)和截断 TFPI 构建体研究 TFPI 的三个 Kunitz 结构域(KDs)在 FVIIa 抑制中的作用。

方法

用 FVIIa 特异性显色底物定量测定 TFPIfl/TFPI 构建体对有/无再脂化组织因子(TF)或可溶性 TF(sTF)的 FVIIa 抑制作用。

结果和结论

TFPIfl 通过单相反应抑制 TF-FVIIa,在低 TFPIfl 浓度下反应相当缓慢(在 2nm TFPI 时 t½≈5min),Ki 为 4.6nm。在 sTF 存在且无 TF 时,TFPIfl 对 FVIIa 的抑制作用较差,Ki 值分别为 122nm 和 1118nm,这表明磷脂和 TF 显著促进 TFPIfl 对 FVIIa 的抑制作用。无 KD3-C 末端的 TFPI 构建体(TFPI1-150 和 KD1-KD2)在抑制 TF-FVIIa 和 sTF-FVIIa 方面比 TFPIfl 有效 7-10 倍,表明 KD3-C 末端显著促进 TFPI 对 FVIIa 的直接抑制。与 KD1-KD2 相比,KD1 是一种较差的 TF-FVIIa 抑制剂(Ki=434nm),这表明 TFPI 的 KD2 结构域也有助于 FVIIa 的抑制。蛋白 S 刺激 TFPIfl 对 TF-FVIIa 的抑制作用(Ki=0.7nm)。在 FXa 存在下,TFPIfl、TFPI1-150 和 KD1-KD2 形成紧密的四元 TF-FVIIa-TFPI-FXa 复合物,Ki 值分别<0.15nm、0.5nm 和 0.8nm,表明 KD3-C 末端不是形成四元复合物的必要条件。磷脂和 FXa 的 Gla 结构域是形成四元复合物所必需的。

相似文献

1
Direct inhibition of factor VIIa by TFPI and TFPI constructs.直接抑制因子 VIIa 的 TFPI 和 TFPI 构建体。
J Thromb Haemost. 2013 Apr;11(4):704-14. doi: 10.1111/jth.12152.
2
Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.组织因子抑制物:TFPI 和 TFPI 构建体对因子 VIIa 催化的因子 IX 和因子 X 的激活作用。
J Thromb Haemost. 2014 Nov;12(11):1826-37. doi: 10.1111/jth.12713. Epub 2014 Oct 12.
3
The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.组织因子途径抑制剂的 Kunitz 1 结构域和 Kunitz 3 结构域对于有效抑制因子 Xa 是必需的。
Thromb Haemost. 2012 Aug;108(2):266-76. doi: 10.1160/TH11-12-0902. Epub 2012 May 25.
4
Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor.探究四聚体复合物组织因子-因子VIIa-因子Xa-组织因子途径抑制剂中因子Xa与组织因子之间的界面。
Eur J Biochem. 2003 Jun;270(12):2576-82. doi: 10.1046/j.1432-1033.2003.03625.x.
5
Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).小分子肽可阻断组织因子途径抑制物(TFPI)对因子 Xa 和组织因子-因子 VIIa 的抑制作用。
J Biol Chem. 2014 Jan 17;289(3):1732-41. doi: 10.1074/jbc.M113.533836. Epub 2013 Nov 25.
6
Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition.凝血因子Xa-组织因子途径抑制物对组织因子-凝血因子VIIa催化的凝血因子X活化的抑制作用。关于磷脂膜组成影响的旋转圆盘研究。
J Biol Chem. 1999 Oct 1;274(40):28225-32. doi: 10.1074/jbc.274.40.28225.
7
Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.组织因子途径抑制剂的 Xa 和 VIIa 因子抑制作用被针对其 Kunitz-1 结构域的单克隆抗体所阻断。
J Thromb Haemost. 2018 May;16(5):893-904. doi: 10.1111/jth.14000. Epub 2018 Apr 6.
8
Role of the Gla and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes.凝血因子X的γ-羧基谷氨酸(Gla)结构域和首个表皮生长因子样结构域在凝血酶原酶及组织因子-凝血因子VIIa复合物中的作用
J Biol Chem. 2003 Mar 21;278(12):10393-9. doi: 10.1074/jbc.M212144200. Epub 2003 Jan 15.
9
Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.艾可洛瑞斯(Ixolaris)是一种来自肩突硬蜱(Ixodes scapularis)唾液腺的新型重组组织因子途径抑制剂(TFPI):确定X因子和Xa因子作为抑制VIIa因子/组织因子复合物的支架。
Blood. 2002 May 15;99(10):3602-12. doi: 10.1182/blood-2001-12-0237.
10
Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.全长和截短的重组组织因子途径抑制物(TFPI)的抑制特性。有证据表明,TFPI的第三个Kunitz型结构域对于抑制细胞表面的因子VIIa-组织因子复合物并非必不可少。
J Biol Chem. 1993 Apr 25;268(12):8704-10.

引用本文的文献

1
Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study.罕见出血性疾病患者的靶向外显子组分析:来自荷兰罕见出血性疾病研究的数据。
Res Pract Thromb Haemost. 2024 Jun 17;8(4):102477. doi: 10.1016/j.rpth.2024.102477. eCollection 2024 May.
2
A Molecular Revolution in the Treatment of Hemophilia.血友病治疗的分子革命。
Mol Ther. 2020 Apr 8;28(4):997-1015. doi: 10.1016/j.ymthe.2019.11.006. Epub 2019 Nov 13.
3
Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.
因子V短型和蛋白S作为协同组织因子途径抑制剂(TFPIα)辅因子。
Res Pract Thromb Haemost. 2017 Dec 20;2(1):114-124. doi: 10.1002/rth2.12057. eCollection 2018 Jan.
4
Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.组织因子途径抑制物-α在低促凝强度下单核细胞依赖的纤维蛋白形成中起抑制作用。
Thromb Haemost. 2018 Mar;118(3):502-513. doi: 10.1055/s-0038-1627453. Epub 2018 Feb 16.
5
Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.在需要使用体外循环的心脏手术后,使用不同止血剂在体外校正凝血酶生成。
Blood Coagul Fibrinolysis. 2015 Jun;26(4):357-67. doi: 10.1097/MBC.0000000000000243.
6
Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.延长半衰期重组FIXFc在B型血友病治疗中的临床应用价值及患者观点
Patient Prefer Adherence. 2014 Aug 8;8:1073-83. doi: 10.2147/PPA.S54951. eCollection 2014.
7
Biology of tissue factor pathway inhibitor.组织因子途径抑制物的生物学特性。
Blood. 2014 May 8;123(19):2934-43. doi: 10.1182/blood-2013-11-512764. Epub 2014 Mar 11.
8
Molecular approaches for improved clotting factors for hemophilia.用于提高血友病凝血因子的分子方法。
Blood. 2013 Nov 21;122(22):3568-74. doi: 10.1182/blood-2013-07-498261. Epub 2013 Sep 24.